MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

osimertinib resistance

  • Home
  • osimertinib resistance
Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study
Posted innews Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

Posted by By MedXY 10/25/2025
This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.
Read More
Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study
Posted inClinical Updates news Oncology Specialties

Savolitinib Plus Osimertinib: A Promising Oral Combination for MET-Driven Resistance in EGFR-Mutated Advanced NSCLC – Insights from the SAVANNAH Phase II Study

Posted by By MedXY 08/08/2025
Savolitinib plus osimertinib showed clinically meaningful responses in patients with EGFR-mutated advanced NSCLC and high MET overexpression/amplification after progression on first-line osimertinib, offering a new targeted therapy option.
Read More
  • Enhanced Risk Stratification for Pediatric Tracheostomy Hospitalizations: Evaluating a Novel Tracheostomy-Specific Tier System
  • Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children
  • Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications
  • Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave
  • Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top